Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | AMP-binding enzyme family protein | 0.009 | 0.3935 | 1 |
Mycobacterium ulcerans | long-chain-acyl-CoA synthetase | 0.009 | 0.3935 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.0921 | 0.234 |
Trypanosoma cruzi | fatty acid transporter protein-like, putative | 0.0083 | 0.358 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0016 | 0.0031 | 0.008 |
Echinococcus multilocularis | musashi | 0.0033 | 0.0921 | 0.0892 |
Trypanosoma cruzi | fatty acid transporter protein-like, putative | 0.0083 | 0.358 | 0.5 |
Echinococcus multilocularis | long chain fatty acid transport protein 4 | 0.0083 | 0.358 | 0.356 |
Leishmania major | fatty acid transporter protein-like protein | 0.0082 | 0.3523 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0889 | 0.226 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0123 | 0.0312 |
Echinococcus multilocularis | lamin | 0.0033 | 0.0921 | 0.0892 |
Onchocerca volvulus | 0.0033 | 0.0921 | 0.5 | |
Schistosoma mansoni | FFA transport protein | 0.0083 | 0.358 | 0.293 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.0921 | 0.0892 |
Brugia malayi | AMP-binding enzyme family protein | 0.009 | 0.3935 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.0921 | 0.0892 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0921 | 0.234 |
Onchocerca volvulus | 0.0033 | 0.0921 | 0.5 | |
Echinococcus granulosus | lamin | 0.0033 | 0.0921 | 0.0892 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD6 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0082 | 0.3523 | 0.5 |
Echinococcus granulosus | long chain fatty acid transport protein 4 | 0.0083 | 0.358 | 0.356 |
Echinococcus multilocularis | geminin | 0.0205 | 1 | 1 |
Mycobacterium leprae | possible long-chain acyl-CoA synthase | 0.0082 | 0.3523 | 0.5 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.0921 | 0.2093 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.0921 | 0.234 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.0921 | 0.2093 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.0921 | 0.0892 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.1158 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 2.2387 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.